Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and GHK-Cu — mechanism, dosing, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma by Loren Pickart in 1973. Plasma GHK declines with age. It is best established as a topical cosmetic ingredient for photoaged skin; it is NOT an FDA-approved drug in any jurisdiction.
BPC-157
GHK-Cu
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage. Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses commonly used on the grey market.
Key references
Peer-reviewed evidence is strongest for topical application in photoaging and wound healing (controlled human studies). Microarray work by Pickart and colleagues reports modulation of ~4,000 genes. Injectable (SubQ) use for systemic effects is a grey-market practice with little or no controlled human data. Not FDA-approved; appears on FDA's Category 1 bulk substances nominated list for compounding.
Key references
BPC-157 (Recovery) and GHK-Cu (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs